Minovia Therapeutics is a clinical stage company and the first to use mitochondrial cell therapy approach with the hope to bring life-changing, meaningful therapies to people affected with mitochondrial diseases, through our Mitochondrial Augmentation Therapy (MAT) platform
Watch Movie ►
Mitochondria are unique organelles producing most of the cells’ energy demands and perform multiple crucial functions, impacting cell biology and health
A heterogeneous group of disorders caused by mutations or deletions in nuclear or mitochondrial DNA (mtDNA), displaying a wide range of severity and phenotypes
Mitochondrial Augmentation Therapy (MAT) is an investigational therapy targeting the root-cause of mitochondrial diseases, as rare or common as they may be
Mitochondrial Augmentation Therapy (MAT) enriches the patients’ hematopoietic stem and progenitor cells with healthy mitochondria isolated from a healthy donor.
Developing transformative therapies to patients requires collaborative spirit and joint efforts from many parties. We believe in cross-discipline collaboration and partner with others who share our commitment and purpose.
We value our partnerships with Patients’ Advocacy Groups. Their insights and collaboration ensure that the voices of mitochondrial patients are heard and applied to our development plans and inspire our devotion.
Bringing together our expertise in science, technology and manufacturing to accelerate the collective understanding of mitochondrial diseases and deliver therapy that is meaningful to patients.